Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Gaia BioMedicine, a Japan-based cancer immuno-cellular therapeutics developer spun out of Kyushu University, has secured ¥1.3bn ($11.9m) in a series B round backed by Osaka University Venture Capital (OUVC), a vehicle for Osaka University. The round was led by financial services firm Mitsubishi UFJ subsidiary Mitsubishi UFJ Capital’s Life Science Fund 2 and also included financial services provider SBI subsidiary SBI Investment, pharmaceutical firm Hisamitsu Pharmaceutical and robotics Cyberdyne’s CEJ Capital unit’s CEJ Fund, in addition to its series A…
